СОВРЕМЕННЫЙ ВЗГЛЯД НА ЭФФЕКТИВНОСТЬ ТЕРАПИИ ПОСТМЕНОПАУЗАЛЬНОГО ОСТЕОПОРОЗА. ИННОВАЦИОННЫЕ ПРЕПАРАТЫ ТАРГЕТНОЙ ТЕРАПИИ

Постепенное увеличение продолжительности жизни человека, стремление к улучшению ее качества требует улучшения результатов профилактики и лечения остеопороза. Основную часть лиц, подверженных ОП, составляют женщины в менопаузе. Разносторонний подход к проблеме восстановления баланса костного метаболизма привел к внедрению в практику препаратов с различными механизмами действия. В последнее время крайне важным аспектом является повышение приверженности к лечению пациентов, получающих многолетнее лечение остеопороза. Инновационным шагом является внедрение в практику применения нового препарата моноклонального человеческого антитела к лиганду RANK деносумаб. В обзоре представлены результаты сравнительных многоцентровых слепых рандомизированных исследований эффективности деносумаба и пероральных бисфосфонатов. Показано более выраженное достоверно влияние деносумаба (подкожно 60 мг 1 раз в 6 мес.) на прирост МПК во всех отделах скелета (как богатых трабекулярной, так и кортикальной костной тканью), значимое снижение риска переломов при хорошей переносимости лечения.

остеопороз, переломы, традиционная и таргетная терапия остеопороза, деносумаб

1. Остеопороз. Диагностика, профилактика и лечение. клинические рекомендации. Под ред. О.М. Лесняк, Л.И. Беневоленской. М.:гОЭТАР-Медиа, 2009, 272 с.

2. NIH Consensus Development Conference on Osteoporosis and Therapy.JAMA,2000.№287:785-795.

3. Astrand J, Thorngren KG, Tagil M. One fracture is enough! Experience with a prospective and consecutive osteoporosis screening program with 239 fracture patients. Acta Orthop. 2006 Feb;77(1):3-8.

4. Follin SL, Black JN, McDermott MT. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy. 2003 Feb;23(2):190-8.

5. О.В.Добровольская, Н.В. Демин, Н.В. Торопцова Состояние минеральной плотности костной ткани у женщин, перенесших малотравматичный перелом в возрасте 50 лет и старше.Остеопороз и остеопатии. 2012. № 2. С. 9-12.

6. Burghardt AJ, Kazakia GJ, Ramachandran S,et al. Ageand gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia.J Bone Miner Res. 2010 May; 25(5):983-93.

7. Kazakia GJ, Burghardt AJ, Link TM Majumdar S. Variations Morphological and biomechanical indices at the distal radius in subjects with identical BMD. J Biomech. 2011 Jan 11;44(2):257-66.

8. Goldenstein J, Kazakia G, Majumdar S. In vivo evaluation of the presence of bone marrow in cortical porosity in postmenopausal osteopenic women. Ann Biomed Eng. 2010 Feb;38(2):235-46.

9. Burghardt AJ, Pialat JB, Kazakia GJ et al. Multicenter precision of cortical and trabecular bone quality measures assessed by high-resolution peripheral quantitative computed tomography. J Bone Miner Res. 2013 Mar;28(3):524-36.

10. Kazakia GJ, Nirody JA, Bernstein G et al. Ageand gender-related differences in cortical geometry and microstructure: Improved sensitivity by regional analysis. Bone. 2013 Feb;52(2):623-31.

11. Wainwright SA, Marshall Lm, Ensrud KE et al. Study of Osteoporotic Fractures Research Group.Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005 May;90(5):2787-93.

12. Hanley D A, J D Adachi, A Bell, and V Brown Denosumab: mechanism of action and clinical outcomes Int J Clin Pract. 2012 December; 66(12): 1139-1146.

13. Hofbauer L, Kuhne C, Viereck V The OPG/RANKL/RANK system in metabolic bone diseases J Musculoskel Neuron Interact 2004; 4(3):268-275.

14. Horwood NJ, Elliott J, Martin TJ, Gillespie MT.Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998; 139:4743-4746.

15. Itoh K, Udagawa N, Matsuzaki K, et al. Importance of membraneor matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 2000; 15:1766-1775.

16. Kanzawa M, Sugimoto T, Kanatani M, Chihara K. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol 2000; 142:661-664.

17. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 1999; 140:3552-3561.

18. Tsukii K, Shima N, Mochizuki S et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998; 246:337-341.

19. Onyia JE, Miles RR, Yang X. et al. In vivo demonstration that parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 2000; 15:8630-871.

20. Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 2001; 280:831-835.

21. Fu Q, Jilka RL, Manolagas SC, O‘Brien CA. Parathyroid hormone stimulates receptor activator of NFIB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 2002; 277:48868-48875.

22. Kondo H, Guo J, Bringhurst FR. Cyclic adenosine monophosphate/ protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res 2002; 17:1667-1679.

23. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003; 89:180-190.

24. Seck T, Diel I, Bismar H, Ziegler R, Pfeilschifter J. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur J Endocrinol 2001; 145:199-205.

25. Stilgren LS, Hegedus LM, Beck-Nielsen H, Abrahamsen B. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int 2003; 73:210-216.

26. Nakchbandi I, Lang R, Kinder B, Insogna K The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008 Mar;93(3):967-73.

27. Robert L. Jilka Molecular and cellular mechanisms of the anabolic effect of intermittent PTH Bone. 2007 June; 40(6): 1434-1446.

28. Митрохина Т.В. Юренева С.В., Майчук Е.Ю. и соавт. минеральная плотность кости и состояние сосудистой стенки на фоне длительной гормональной терапии у женщин после овариэктомии. Остеопороз и остеопатии 2012 №2. с.13-17

29. Dr. Jae H. Kang, ScD and Dr. Francine Grodstein, ScD. Postmenopausal Hormone Therapy, Timing of Initiation, APOE and Cognitive DeclineNeurobiol Aging. 2012 July; 33(7): 1129-1137.

30. M. Almeida, S. Iyer, M. Martin-Millan et al. Estrogen receptor-a signaling in osteoblast progenitors stimulates cortical bone accrual J Clin Invest. 2013 January 2; 123(1): 394-404.

31. Мокрышева Н.Г. Рожинская Л.Я. возможности альтернативного консервативного ведения пациентов с первичным гиперпаратиреозом на фоне фосамакса. Зффективаная фармакотерапия. м.2012.с.18-25.

32. Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone. 2007 Nov;41(5):882-7. Epub 2007 Jul 18.

33. Harrold LR, Mazor KM, Peterson D, Naz N. et al. Patients' knowledge and beliefs concerning gout and its treatment: a population based study.BMC Musculoskelet Disord. 2012 Sep 21;13:180.

34. Cotte FE, Fardellone P, Mercier F et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010 Jan;21(1):145-55.

35. Emkey R, Koltun W, Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005 Dec;21(12):1895-903.

36. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine. 2008 May;75(3):303-10. Epub 2007 Oct 22.

37. Solomon DH, Morris C, Cheng H. et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc. 2005 Feb;80(2):194-202.

38. Solomon DH, Brookhart MA, Gandhi TK. et al. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med. 2004 Dec 15;117(12):919-24.

39. Brod M, Cobden D, Lammert M, et al. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes. 2007 Feb 7;5:8.

40. Reid IR, Miller PD, Brown JP, et al.; Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010 Oct;25(10):2256-65.

41. Brown JP, Roux C, Torring O. et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013 Apr;28(4):746-52. doi: 10.1002/jbmr.1808.

42. Orwoll E, Teglbj^rg CS, Langdahl BL et al.A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9.

43. Elise F. Morgan, et al. Micro-Computed Tomography Assessment of Fracture Healing: Relationships among Callus Structure, Composition, and Mechanical Function Bone. 2009 February; 44(2): 335-344.

44. Brown JP, Prince RL, Deal C. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover inpostmenopausal women with low bone mass: randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 Jan;24(1):153-61.

45. C.Roux,A. Fahrleitner-Pammer, et al. A Randomized Study to Evaluate the Safety and Efficacy of Denosumab and rezidronate in Postmenopausal Women ASBMR; Minneapolis, MN; October 12-15, 2012.

46. Recknor et al. A Randomized Open-label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Suboptimally Treated With Daily or Weekly Bishosphonates (TTI study) ASBMR; Minneapolis, MN; October 12-15, 2012.

47. Lin T, Wang C, Cai XZ, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract. 2012 Apr;66(4):399-408.

48. Freemantle N, Cooper C, Diez-Perez A et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int. 2013 Jan;24(1):209-17.

49. Block GA, Bone HG, Fang L, Lee E, Padhi D.A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012 Jul;27(7):1471-9.

50. Jamal SA, Ljunggren O, Stehman-Breen C. et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011 Aug;26(8):1829-35.

51. C. M. R. Brandao; G. P. M. Machado F. A. Acurcio Pharmacoeconomic analysis of strategies to treat postmenopausal osteoporosis: a systematic review Rev. Bras. Reumatol. vol.52 no.6 Sao Paulo Nov./Dec. 2012.

52. Hiligsmann M, Ethgen O, Bruyere O. et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009;12(5):687-96.

53. Stevenson M, Jones ML, De Nigris E. et al. systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9(22):1-160.

54. Rosner AJ, Grima DT, Torrance GW. et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998;14 (5):559-73.

55. Iglesias CP, Torgerson DJ, Bearne A, Bose U. The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002;95(5):305-11.

56. Johnell O, Jonsson B, Jonsson L, Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003;21(5):305-14.

57. Brecht JG, Kruse HP, Felsenberg D, et al. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 2003;23(4):93-105.

58. Borgstrom F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006;17(7):996-1007.

59. Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 2006;22(7):1425-36.

60. Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166(11):1209-17.

61. Strom O, Borgstrom F, Sen SS. et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18 (8):1047-61.

62. Earnashaw SR, Graham CN, Ettinger B. et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin 2007;23(10):2517-29.

63. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am H Manag Care 2008;14(9):605-15.

64. Wasserfallen JB, Krieg MA, Greiner RA, Lamy O. Cost-effectiveness and cost-utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective. J Med Econ 2008;11(3):499-523.

65. Berto P, Maggi S, Noale M, Lopatriello S. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. Aging Clin Exp Res 2010;22(2):179-88.

66. Silva LK. Avaliasao tecnologica em saude: densitometria ossea e terapeuticas alternativas na osteoporose pos-menopausa. Cad Saude Publica 2003;19(4):987-1003.

67. Kanis JA, Borgstrom F, Johnell O, Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004;15(11):862-71.

68. Hiligsmann M, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010;46(2):440-6.

69. Hiligsmann M, Bruyere O, Reginster JY. Cost-utility of longterm strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 2010;21(1):157-65.

70. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010;47(1):34-40.

71. Jonsson B, Strom O, Eisman JA. et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011;22(3):967-82.

72. Hiligsmann M, Reginster JY. Cost-effectiveness of denosumab compared with oral bisphosphonates int the treatment of postmenopausal osteoporotic women in Belgium. Pharmacoeconomics 2011;29(10):895-911.

73. Diez-Perez A, Adachi JD. D.Agnusdei. JP Bilezikian, et al; IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis Osteoporos Int. 2012 Dec;23(12):2769-74.

74. Eisman JA, Bogoch ER et al; ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012 Oct;27(10):2039-46.

75. Сагаловски С. Остеопороз: клеточно-молекулярные механизмы развития и мишени для поиска новых средств лечения заболевания. Остеопороз и остеопатии. 2012 г. №1, стр. 150-22.